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Methods: We conducted an individual patient data pooled analysis of 7 prospective cohort studies that recruited
patients with AF and recent cerebral ischemia. We compared patients taking oral anticoagulants (vitamin K antagonists
[VKA] or direct oral anticoagulants [DOAC]) prior to index event (OACprior) with those without prior oral anticoagulation
(OACnaive). We further compared those who changed the type (ie, from VKA or DOAC, vice versa, or DOAC to DOAC)
of anticoagulation (OACchanged) with those who continued the same anticoagulation as secondary prevention
(OACunchanged). Time to recurrent acute ischemic stroke (AIS) was analyzed using multivariate competing risk Fine–Gray
models to calculate hazard ratios (HRs) and 95% confidence intervals (CIs).
Results: We included 5,413 patients (median age = 78 years [interquartile range (IQR) = 71–84 years]; 5,136 [96.7%]
had ischemic stroke as the index event, median National Institutes of Health Stroke Scale on admission = 6
[IQR = 2–12]). The median CHA2DS2-Vasc score (congestive heart failure, hypertension, age≥ 75 years, diabetes
mellitus, stroke/transient ischemic attack, vascular disease, age 65–74 years, sex category) was 5 (IQR = 4–6) and was
similar for OACprior (n = 1,195) and OACnaive (n = 4,119, p = 0.103). During 6,128 patient-years of follow-up,
289 patients had AIS (4.7% per year, 95% CI = 4.2–5.3%). OACprior was associated with an increased risk of AIS
(HR = 1.6, 95% CI = 1.2–2.3, p = 0.005). OACchanged (n = 307) was not associated with decreased risk of AIS (HR = 1.2,
95% CI = 0.7–2.1, p = 0.415) compared with OACunchanged (n = 585).
Interpretation: Patients with AF who have an ischemic stroke despite previous oral anticoagulation are at a higher risk
for recurrent ischemic stroke despite a CHA2DS2-Vasc score similar to those without prior oral anticoagulation. Better
prevention strategies are needed for this high-risk patient group.
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Oral anticoagulation substantially reduces the risk forischemic stroke and systemic embolism in patients
with atrial fibrillation (AF). Nevertheless, patients with AF
may still have an ischemic stroke despite taking oral antico-
agulants.1 This is often regarded as a treatment failure,
whose mechanisms include incompliance, reduced pharma-
cological efficacy of the anticoagulant in individual patients,
or other factors such as alternative stroke mechanisms (eg,
small vessel occlusion).2 These patients might be at particu-
larly high risk of further ischemic stroke events, but this has
not been investigated. Moreover, the optimal prevention
strategy to reduce further recurrence risk in such patients is
unknown. Direct oral anticoagulants (DOAC) are a proven
effective alternative to vitamin K antagonists (VKA) for oral
anticoagulation in patients with AF.3 Among patients with
an ischemic stroke despite anticoagulant therapy, it is
unknown whether changing the type of anticoagulant
(VKA to DOAC, DOAC to VKA, or switching to an alter-
native DOAC) reduces the risk of recurrence.
We aimed to answer the following questions in
patients with AF and an index acute ischemic stroke or
transient ischemic attack (TIA). First, are patients who
have an ischemic stroke or TIA despite taking oral antico-
agulants (VKA or DOAC) at increased risk of recurrent
acute ischemic stroke (AIS) or other outcome events? Sec-
ond, after the index event, is changing the type of antico-
agulant (VKA or DOAC or type of DOAC) associated
with reduced rates of AIS?
Patients and Methods
Study Design and Study Population
We used pooled individual patient data from an
established international collaboration of investigator-
initiated prospective cohort studies.4 The following studies
were included: the single-center prospective cohort studies
from Verona, Italy,5 Erlangen, Germany,6 and Basel,
Switzerland (Novel Oral Anticoagulants in Stroke Patients
[NOACISP])7; the multicenter cohort studies Early
Recurrence and Cerebral Bleeding in Patients with Acute
Ischemic Stroke and Atrial Fibrillation (RAF8 and RAF-
NOAC9; 29 centers in Europe, Asia, and North America);
the Clinical Relevance of Microbleeds in Stroke study
(CROMIS-2; 79 centers in the United Kingdom and 1 in
The Netherlands)10,11; and the Stroke Acute Management
with Urgent Risk-Factor Assessment and Improvement
Study on Anticoagulant Therapy in Nonvalvular Atrial
Fibrillation (SAMURAI-NVAF, 18 centers in Japan).12,13
Details about the participating studies can be obtained
from the published studies4–12,14 and prior publications.4
Inclusion and Exclusion Criteria
We included patients with: (1) recent ischemic stroke or
TIA; (2) diagnosis of nonvalvular AF either known prior
to the index event or detected after the event; (3) informa-
tion on anticoagulation therapy prior to and after index
event available; and (4) systematic follow-up for at least
3 months or longer after the index event for the presence
or absence of recurrent AIS, intracerebral hemorrhage, and
death. We excluded patients with: (1) mechanical heart
valves; (2) rheumatic or severe mitral valve stenosis; or
(3) missing information on antithrombotic treatment
before the index event.
Data Collection and Baseline Data
Data were collected as described in prior publications15,16:
briefly, local investigators filled in standardized forms with
predefined variables using individual patient data from
their corresponding study database. Completed forms
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were collected at the coordinating center in Basel, Switzer-
land, where the pooled analysis was performed. The
corresponding author (DJS) had full access to all the data
in the study and takes responsibility for its integrity and
the data analysis.
Baseline Data
The following baseline variables were recorded and pro-
vided by the participating studies: age, sex, type of index
event (AIS or TIA); antithrombotic treatment
(no treatment, antiplatelet agents, VKA or DOAC includ-
ing type of DOAC) before and after index event; interna-
tional normalized ration (INR) at index event (if patient was
on VKA therapy); time from index event to first dose of
VKA or DOAC; stroke severity on admission as assessed by
the National Institutes of Health Stroke Scale (NIHSS)17;
and use of intravenous thrombolysis or endovascular reperfu-
sion therapy for index stroke. DOAC therapy was defined as
one of the following drugs and dosages: apixaban 2.5mg or
5mg twice daily; dabigatran 110mg or 150mg twice daily;
edoxaban 30mg or 60mg once daily; or rivaroxaban 15mg or
20mg once daily (10mg or 20mg once daily in Japan,
according to the results from a domestic trial18). VKA therapy
was defined as treatment with phenprocoumon (NOACISP,
Erlangen) or acenocoumarol/warfarin (SAMURAI-NVAF,
RAF/RAF-DOAC, CROMIS-2, and Verona). The choice of
treatment was decided by the treating physician.
The following risk factors were collected: history of
ischemic stroke; history of intracranial hemorrhage; diabetes
mellitus; hypertension; hypercholesterolemia; diagnosis of
AF (known before stroke vs diagnosed after stroke)19–21;
renal function (creatinine clearance [CrCl] in ml/min using
the Chronic Kidney Disease Epidemiology Collaboration
[CKD-EPI] equation,22 which was further classified into
normal renal function defined as CrCl > 50ml/min, modest
renal failure defined as CrCl = 30–50ml/min, and severe
kidney failure defined as CrCl < 30ml/min); current
smoking; the CHA2DS2-Vasc score (congestive heart fail-
ure, hypertension, age ≥ 75 years, diabetes mellitus, stroke/
transient ischemic attack, vascular disease, age 65–74 years,
sex category)23; and the HAS-BLED score (hypertension,
abnormal renal/liver function, stroke, bleeding history or
predisposition, labile international normalized ratio, elderly,
drugs/alcohol)24 designed to predict future AIS and major
bleeding complications, respectively.
Follow-Up
All patients were followed up for at least 3 months after
index event; in some studies, follow-up data for up to
5.4 years after index event were available. During follow-
up, occurrence of the following outcome events was
assessed: (1) recurrent AIS defined as new neurological
symptoms and evidence for ischemic stroke on computed
tomography (CT) or magnetic resonance imaging (MRI);
(2) intracerebral hemorrhage (ICH) defined as new neuro-
logical symptoms associated with the detection of intrace-
rebral hemorrhage on CT or MRI as defined as part of
the International Society on Thrombosis and Haemostasis
criteria25; and (3) all-cause mortality (including fatal
stroke). For patients on VKA, INR at outcome event (AIS
or ICH) was collected if available. If available, information
on time in therapeutic range for patients on VKA during
follow-up was collected, dichotomized as poor (<60%)
and good (>60%). Among patients taking DOAC, self-
reported adherence was dichotomized as fully adherent
(no missing dosage since last study visit) or nonadherent
(at least 1 missing dosage since last study visit) based on
information provided by the patient.26
Outcome
The primary outcome of this analysis was recurrent AIS. Sec-
ondary endpoints were symptomatic ICH and mortality.
Ethics
The NOACISP LONG-TERM registry and the current anal-
ysis of pooled individual patient data were approved by the
ethics committee in Basel, Switzerland (EKNZ 2014-027).
Patients provided written consent for participation in
NOACISP LONG-TERM. The requirement for additional
local ethical approval differed among participating centers and
was acquired by the local principal investigator as well as writ-
ten informed consent by the patient if necessary. The
SAMURAI-NVAF registry and the collaboration with the
joint initiative were approved by the ethics committee in the
National Cerebral and Cardiovascular Center (M23-18-3 and
M29-077). CROMIS-2 was approved by the National
Research Ethics Committee, London (Queen Square).
Patients with capacity gave informed written consent. When
patients could not consent, we obtained written consent from
a proxy as defined by relevant local legislation.
Statistical Analysis Plan
The statistical analysis was carried out using Stata (v14;
StataCorp, College Station, Texas). The primary analysis
was conducted in the entire cohort comparing patients
with anticoagulation prior to admission (OACprior) with
those without anticoagulation on admission (OACnaive).
OACprior was defined as a patient reporting to be on ther-
apy with VKA or DOAC (apixaban, dabigatran,
edoxaban, or rivaroxaban) at the time of onset of the
index event. OACnaive was defined as patients who were
not on therapy with VKA or DOAC at the time of onset
of the index event. OACnaive included patients who were
on antiplatelet agents or heparin.
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The secondary analysis was conducted in the subgroup
of patients with OACprior. We compared patients in whom
the type of anticoagulant was changed after the index event
(OACchanged, the first oral anticoagulant the patient received
after the index event) with those who continued the same
type of anticoagulant after the event that they used already
prior to having a stroke or TIA (OACunchanged). OACchanged
was defined as one of the following: VKA prior to index
event to DOAC after; DOAC prior to index event to VKA
after; or changing type of DOAC (apixaban, dabigatran,
edoxaban, or rivaroxaban). We excluded patients with severe
renal impairment (CrCl < 30ml/min) from this subanalysis,
as DOACs are contraindicated in these patients. We also
excluded patients in whom the type of anticoagulation
before or after the index event was not known.
We compared demographic and clinical baseline
characteristics among groups using the Pearson χ2 test for
categorical variables and the Mann–Whitney U test for
continuous variables. We calculated the annualized rate of
outcome events (total of observed events/patient-years of
follow-up). For all analysis, we calculated time from
starting first anticoagulation until first occurrence of an
outcome event. In case of multiple events in the same
patient, we only considered the time until first event. For
the primary analysis, we constructed unadjusted cumula-
tive incidence functions for outcomes and compared
groups using the log-rank test. We investigated the associ-
ation between baseline characteristics and outcomes using
univariate Cox proportional hazard regression models.
To further analyze the associations between groups
and outcomes (AIS and ICH), we used multivariate com-
peting risk models (competing risk: death) using the Fine–
Gray model27 including the following prespecified variables:
age; sex; history of stroke; diabetes mellitus; hypertension;
NIHSS on admission; impaired renal function (CrCl
< 50ml/min); diagnosis of AF (known before stroke vs diag-
nosed after stroke)19–21; and anticoagulation after index
stroke (any anticoagulation vs no anticoagulation, only used
in the primary analysis as all patients in the secondary anal-
ysis were using anticoagulants after the event). Additionally,
shared frailty for study was introduced into all multivariate
models to account for differences in local activity of care,
resources, and ethnicity.
All analyses were conducted in the intention-to-treat
population using the first prescribed oral anticoagulant after
index stroke (ie, DOAC or VKA). We performed a post
hoc sensitivity in the on-treatment population including
only patients with available information about changes in
anticoagulant therapy during follow-up. For sensitivity ana-
lyses, we used change in anticoagulation (ie, on treatment vs
discontinuation) as a time-varying covariate. We calculated
hazard ratios (HRs) with 95% confidence intervals (CIs).
Results
The final cohort for this analysis comprised 5,314 of
5,421 patients (98.0%) from the pooled data set of indi-
vidual patient data (study flow chart in Fig 1). In this
cohort, 2,559 patients (48%) were female, and 5,136
patients (96.7%) had an ischemic stroke as index event.
The median age was 78 years (interquartile range [IQR] =
71–84 years), and the median NIHSS on admission was
6 (IQR = 2–12). Prior to the index event, 3,014 patients
(56.7%) had received no antithrombotic treatment, 1,089
(20.5%) were on antiplatelets, 1,195 (22.5%) were on
treatment with any oral anticoagulant (161 on DOAC,
865 on VKA, and in 169 the type of oral anticoagulation
was not specified), and 16 (0.3%) were on other anti-
thrombotic medications (ie, heparins). In patients on
VKA prior to index stroke who had available data on INR
(842 of 865 patients, 97.3%), the INR was <2.0 in
615 patients (73.0%), 2.0 to 3.0 in 185 patients (22.0%),
and >3.0 in 42 patients (5.0%). After the index event,
4,929 patients (92.8%) were taking anticoagulants
(DOAC in 2,716 patients; VKA in 2,213 patients),
359 patients (6.8%) were taking antiplatelet agents, and
26 patients (0.5%) had no antithrombotic therapy. For
patients taking anticoagulants, the median delay between
index event and (re)starting OAC was 5 days
FIGURE 1: Study flow chart. AF = atrial fibrillation; TIA =
transient ischemic attack. [Color figure can be viewed at
www.annalsofneurology.org]
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(IQR = 2–13). For patients using VKA after the event,
information about time in therapeutic range was available
in 924 of 2,213 patients (41.8%). Among these patients,
762 (82.5%) were recorded to have good (>60%) time in
the therapeutic range. Among patients taking DOACs
after the event, information on adherence was available
from only 1 study (NOACISP7,26) for 485 of 2,716
patients (17.6%). During follow-up, 347 of these
485 patients (71.6%) were fully adherent. There was no
difference in full adherence between patients that changed
OAC after the index stroke and those who continued the
same OAC (16 of 72 patients vs 28 of 108 patients;
77.8% vs 74.1% fully adherent, p > 0.05).
Primary Analysis: OACprior vs OACnaive
The baseline characteristics of patients with OACprior
(n = 1,195) compared to OACnaive (n = 4,119) are dis-
played in Table 1. Patients with OACprior were older, had
a lower proportion of index ischemic stroke and a lower
NIHSS on admission, and were less often treated with
TABLE 1. Baseline Characteristics of Patients with and without Oral Anticoagulation Therapy prior to Index
Event and Patients Who Did and Did Not Change the Type of Anticoagulation
Primary Analysis Secondary Analysis
OACprior,
n = 1,195
OACnaive,
n = 4,119 p
OACchanged,
n = 307
OACunchanged,
n = 585 p
Agea 79 (73–84) 77 (70–84) <0.001 79 (74–84) 79 (72–83) 0.046
Female (%) 555/1,195 (46.4) 2,004/4,119 (48.7) 0.178 155/307 (50.6) 249/585 (42.6) 0.023
Prior treatment with VKA (%) 865/1,195 (72.4) 0 N/A 291/306 (95.1) 519/584 (88.8) 0.002
Ischemic stroke as index event (%) 1,144/1,195 (95.7) 3,992/4,119 (96.9) 0.045 229/307 (74.6) 519/585 (88.7) 0.002
History of ischemic stroke
(other than index event) (%)
458/1,192 (38.4) 788/4,111 (19.2) <0.001 119/306 (38.9) 222/583 (38.1) 0.828
History of ICH (%) 17/780 (2.2) 34/2,769 (1.2) 0.060 5/275 (1.8) 9/414 (2.2) 1.000
Hypertension (%) 1,026/1,195 (85.9) 2,958/4,089 (72.3) <0.001 259/306 (84.6) 499/584 (85.4) 0.766
Hypercholesterinemia (%) 438/1,026 (42.7) 1,262/3,387 (37.3) 0.002 145/306 (47.4) 240/584 (41.1) 0.075
Smoking (%) 188/1,150 (16.3) 694/4,021 (17.3) 0.505 33/286 (11.5) 80/568 (14.1) 0.336
Diabetes mellitus (%) 442/1,194 (37.0) 890/4,109 (21.7) <0.001 109/305 (35.7) 226/584 (38.7) 0.423
Normal renal function,
CrCl > 50ml/min (%)
638/894 (71.4) 2,638/3,321 (79.4) <0.001 207/273 (75.8) 105/305 (74.4) 0.719
Modest kidney failure,
CrCl = 30–50ml/min (%)
185/894 (20.7) 554/3,321 (16.7) 66/273 (24.2) 105/410 (25.6)
Severe kidney failure,
CrCl < 30ml/min (%)
71/894 (7.9) 129/3,321 (3.9) 0 0
Intravenous thrombolysis (%) 156/1,193 (13.1) 929/4,095 (22.7) <0.001 51/304 (16.8) 60/584 (10.3) 0.007
Intraarterial treatment (%) 48/1,057(4.5) 141/3,897 (3.6) 0.174 15/278 (5.4) 18/483 (3.7) 0.274
NIHSS on admissiona 5 (2–11) 6 (2–12) <0.001 4 (2–10) 5 (2–11 0.222
CHA2DS2-Vasc
a 5 (4–6) 5 (4–6) 0.103 6 (4–6) 5 (4–6) 0.014
HAS-BLEDa 3 (3–4) 3 (3–4) 0.626 3 (2–4) 3 (3–4) 0.097
aMedian (interquartile range).
CHA2DS2-Vasc = congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age
65–74 years, sex category; CrCl = creatinine clearance; HAS-BLED = hypertension, abnormal renal/liver function, stroke, bleeding history or predispo-
sition, labile international normalized ratio, elderly, drugs/alcohol; ICH = intracerebral hemorrhage; N/A = not applicable; NIHSS = National Insti-
tutes of Health Stroke Scale; OACchanged = type of anticoagulant changed after index event; OACnaive = no anticoagulation on admission; OACprior =
anticoagulation prior to admission; OACunchanged = type of anticoagulant not changed after index event.
May 2020 681
Seiffge et al: Stroke Recurrence Risk
intravenous thrombolysis for the index event. They more
often had a history of prior ischemic stroke before the
index event, hypertension, hypercholesterinemia, diabetes
mellitus, and modest or severe kidney failure. The
CHA2DS2-Vasc and HAS-BLED scores did not differ
between the OACprior and OACnaive groups.
The total follow-up time in the primary analysis data
set of 5,314 patients was 6,128 patient-years. During
follow-up, 289 patients had AIS (4.7% per year, 95%
CI = 4.2–5.3%), 90 patients had ICH (1.5% per year,
95% CI = 1.2–1.8%), and 624 patients died (10.2% per
year, 95% CI = 9.4–11.0%).
Figure 2A shows cumulative incidence function cur-
ves for the primary outcome of recurrent AIS. OACprior
had a higher rate of recurrent AIS (log-rank test:
p < 0.0001). There was little difference for ICH (log-rank
test: p = 0.425) and weak evidence for a higher risk of
mortality (log-rank test: p = 0.066). Table 2 displays
annualized event rates for both groups and associations
with outcomes: OACprior was associated with an increased
risk of recurrent AIS both in univariate (HR = 2.0, 95%
CI = 1.5–2.5, p < 0.001) and multivariate competing risk
Fine–Gray analysis (HR = 1.6, 95% CI = 1.2–2.3,
p = 0.005) but not with ICH or mortality.
Secondary Analysis: OACchanged vs OACunchanged
Among the 1,195 patients with OACprior, 892 patients
were included in this secondary analysis (see study flow
FIGURE 2: Cumulative incidence function curves for the main outcome of recurrent acute ischemic stroke. (A) Primary analysis of
patients taking oral anticoagulation prior to the index event (OACprior, dashed line) compared to those not taking anticoagulants
prior to the index event (OACnaive, solid line). (B) Secondary analysis of patients that changed the type of anticoagulation
(OACchanged, dashed line) compared to those who continued the same type of anticoagulation (OACunchanged, solid line). [Color
figure can be viewed at www.annalsofneurology.org]
TABLE 2. Observed and Annualized Rates of Outcome Events in Patients with OACprior and OACnaive and
Univariate and Multivariate Analysis
OACnaive, n = 4,119 OACprior, n = 1,195 Univariate Multivariate
a
Events, nb
Annualized
Rate (95% CI) Events, nb
Annualized
Rate (95% CI)
Hazard Ratio
(95% CI) p
Hazard Ratio
(95% CI) p
AIS 196 3.9 (3.3–4.4) 93 8.9 (7.3–10.8) 2.0 (1.5–2.5) <0.001 1.6 (1.2–2.3) 0.005
ICH 69 1.4 (1.0–1.7) 21 2.0 (1.3–3.1) 1.2 (0.7–2.0) 0.426 1.1 (0.5–2.3) 0.811
Mortality 501 9.9 (9.1–10.7) 123 11.8 (9.9–13.9) 1.2 (1.0–1.5) 0.069 1.1 (0.8–1.4) 0.667
aMultivariate competing risk Fine–Gray analysis was adjusted for the following prespecified variables: age, sex, history of ischemic stroke other than
index event, hypertension, diabetes mellitus, modest or severe kidney failure (creatinine clearance < 50ml/min), diagnosis of atrial fibrillation (known
before the ischemic stroke vs diagnosed after stroke), and treatment with any oral anticoagulant after index event. Study was introduced as a shared
frailty term in this analysis.
bn = number of patients.
AIS = acute ischemic stroke; CI = confidence interval; ICH = intracerebral hemorrhage; OACnaive no anticoagulation on admission; OACprior = anti-
coagulation prior to admission.
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chart Fig 1), in whom type of anticoagulation prior to and
after the index event was known and who did not have
severe kidney failure (CrCl < 30ml/min). The baseline
characteristics of patients with OACchanged (n = 307) com-
pared to OACunchanged (n = 585) are displayed in Table 1.
Patients with OACchanged were older, more often female,
had more often an ischemic stroke as index event, and
had a higher CHA2DS2-VASc score. In the group of
OACchanged, 229 patients (74.6%) changed from VKA to
a DOAC, 26 patients (8.5%) changed from DOAC to
VKA, and 52 patients (16.9%) changed the type of
DOAC. In the group of OACunchanged, 66 patients
(11.3%) were on the same DOAC prior to and after the
index event, and 519 patients (88.7%) were on VKA prior
to and after the index event. In patients in the
OACunchanged group that were on VKA prior to and after
the index event, data on INR were available in 513 of
519 patients (98.8%), 358 patients (69.8%) had INR
< 2.0, 132 patients (25.7%) had INR 2.0 to 3.0, and
23 patients (4.5%) had INR > 3.0 at index event.
The total follow-up time included in the secondary
analysis data set was 894 patient-years. During follow-up,
75 patients had AIS (8.4% per year, 95% CI = 6.7–10.4%),
17 patients had ICH (1.9% per year, 95% CI = 1.1–3.0%),
and 85 patients died (9.5% per year, 95% CI = 7.7–11.6%)
in this subanalysis.
Among patients on VKA (in both groups), data on
INR at recurrent AIS during follow-up were available in
26 of 42 patients (61.9%). In the OACunchanged group,
the INR was <2.0 in 16 of 26 patients (61.5%) and ≥2.0
in 10 of 26 patients (38.5%) for patients on VKA. In the
OACchanged group, the INR at recurrent AIS was available
for only 1 patient on VKA (INR <2.0).
Figure 2B displays cumulative incidence function
curves for the primary outcome of recurrent AIS in the
secondary analysis. OACchanged was associated with a
decreased risk of mortality in univariate (HR = 0.5, 95%
CI = 0.3.–0.9, p = 0.012) but not multivariate analysis
(HR = 0.7, 95% CI = 0.4–1.2, p = 0.177). We did not
find any association of changing OAC with AIS or ICH
(Table 3).
Sensitivity Analysis: On-Treatment Population
We performed a post hoc analysis in the on-treatment
population (3,508 of 5,314 patients with available infor-
mation on therapeutic changes during follow-up; 66.0%).
During follow-up, 409 of 3,508 patients (11.7%) changed
therapy: 122 patients changed the type of DOAC,
88 patients changed from DOAC to VKA, 157 patients
changed from VKA to DOAC, and in 42 patients oral
anticoagulation was discontinued. The results of the main
analysis were confirmed in the on-treatment population
(HR for AIS = 1.8, 95% CI = 1.3–2.5, p < 0.001).
For the secondary analysis, information on changing
anticoagulation during follow-up was available in 689 of
892 patients (77.2%), of whom 129 patients (18.7%)
changed therapy during follow-up: 42 changed the type of
DOAC, 25 changed from DOAC to VKA, 53 changed
from VKA to DOAC, and 9 discontinued anti-
coagulation. The results of the main analysis were con-
firmed in the on-treatment population (HR for AIS = 1.3,
95% CI = 0.7–2.1, p = 0.379).
Discussion
This international collaborative study of 5,314 patients
yielded the following main findings. First, 1,195 patients
TABLE 3. Observed and Annualized Rates of Outcome Events in Patients with OACchanged and OACunchanged and
Univariate and Multivariate Analysis
OACchanged, n = 307 OACunchanged, n = 585 Univariate Multivariate
a
Events, nb
Annualized Rate
(95% CI) Events, nb
Annualized
Rate (95% CI)
Hazard Ratio
(95% CI) p
Hazard Ratio
(95% CI) p
AIS 28 8.8 (5.9–12.4) 47 8.2 (6.1–10.7) 1.1 (0.7–1.7) 0.749 1.2 (0.7–2.1) 0.415
ICH 4 1.3 (0.3–3.2) 13 2.3 (1.2–3.8) 0.6 (0.2–1.8) 0.346 0.8 (0.2–3.2) 0.793
Mortality 19 5.9 (3.6–9.1) 66 11.5 (9.0–14.4) 0.5 (0.3–0.9) 0.012 0.7 (0.4–1.2) 0.177
aMultivariate competing risk Fine–Gray analysis was adjusted for the following prespecified variables: age, sex, history of ischemic stroke other than
index event, hypertension, diabetes mellitus, diagnosis of atrial fibrillation (known before stroke vs diagnosed after stroke), and modest kidney failure
(creatinine clearance = 30–50ml/min). Study was introduced as shared frailty term in this analysis.
bn = number of patients.
AIS = acute ischemic stroke; CI = confidence interval; ICH = intracerebral hemorrhage; OACchanged = type of anticoagulant changed after index event;
OACunchanged = type of anticoagulant not changed after index event.
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(22.5%) had an AIS or TIA despite treatment with oral
anticoagulants. Second, these AF patients with prior anti-
coagulant use more often had cardiovascular risk factors
compared to those who had not received anticoagulation
at the time of the event, but had similar CHA2DS2-Vasc
and HAS-BLED scores. Third, after adjusting for cardio-
vascular risk factors, patients who had a stroke despite
treatment with oral anticoagulants were still at high risk of
recurrent ischemic stroke. Fourth, changing the type of
anticoagulant after the index event was not associated with
a decreased risk of further ischemic strokes.
To the best of our knowledge, this is the first study
addressing the question of whether patients failing anti-
coagulation therapy and having an ischemic stroke or TIA
despite anticoagulant therapy are at subsequent high risk
of further events. Both groups—those who had a stroke
while on anticoagulant therapy and those without prior
anticoagulation therapy—had a median CHA2DS2-VASc
score of 5, corresponding to an estimated risk of 7.2% per
year of ischemic stroke.28 Nevertheless, the actual
observed rate of recurrent ischemic strokes was twice as
high in patients who had their index stroke despite taking
anticoagulants (annualized rate = 8.9%, 95%
CI = 7.3–10.8%) compared to those who were not on
anticoagulation therapy at the time of index stroke (annu-
alized rate = 3.9%, 95% CI = 3.3–4.4%). This raises the
key questions of why patients with OACprior are at
increased risk and what the optimal prevention strategy
might be to reduce this risk.
One potential explanation is nonadherence to pre-
scribed anticoagulation therapy prior to the index event. A
majority (73%) of patients on VKA prior to the index
event had subtherapeutic INR, indicating poor adherence.
Among those patients who continued VKA after the
event, 61% of further recurrent ischemic strokes occurred
at subtherapeutic INR values. In these patients, poor
adherence might thus have played a role, even though
they all had already suffered from a significant outcome
event—ischemic stroke. However, patients who start on
DOACs for secondary prevention generally achieve high
rates of adherence26 making this unlikely to be a full
explanation. Furthermore, patients who were OAC naive
prior to a stroke were reported to have lower rates of
adherence26 than those who had used anticoagulants in
the past, which would bias in the opposite direction from
our findings. In addition, a recent analysis in a study from
Japan found that in patients taking VKA, an INR of
≥2.0 at stroke onset was associated with a higher risk of
recurrent ischemic stroke.29
Genetic variability could be a cause of susceptibility to
recurrent stroke in patients with AF: 2 genes (CYP2C9 and
VKORC1) may play a role in individual patient response to
and efficacy of VKA,30–33 but no such variability of
response is known for DOACs. However, most patients who
changed anticoagulation after the event were switched from
VKA to a DOAC (76%), so a genetic variability in 1 of the
aforementioned genes is not likely to explain the high contin-
ued ischemic stroke risk we observed.
Alternatively, the prior use of anticoagulants might
be for pulmonary embolism or deep vein thrombosis.
These conditions may have been present independent of
AF and could put patients at a higher stroke risk than
patients with pure AF, for example due to a pro-
thrombotic state, paradoxical embolism of increased
inflammatory state. Further monitoring (eg, anti-Xa levels)
could be useful in this population.
Our data show that despite similar median
CHA2DS2-VASc scores, several cerebrovascular risk factors
(hypertension, diabetes, hypercholesterinemia, kidney fail-
ure) were more frequent in patients with prior anti-
coagulation. Furthermore, 38% of patients on prior
anticoagulation had already experienced an ischemic stroke
before the index event in this study. This may point
toward competing stroke risk factors and stroke
etiologies—for example, large artery atherosclerosis or
small vessel disease—that might be less responsive to anti-
coagulation therapy.2 Further research needs to focus on
mechanisms, competing risk factors, and etiology of
(recurrent) stroke in patients taking anticoagulants. This
could include taking into account competing causes as in
the ASCO34 or ASCOD35 (A = atherosclerosis, S = small-
vessel disease, C = cardiac pathology, O = other causes, D =
dissection) causality score systems.
This hypothesis is further supported by our second-
ary analysis, which found that simply changing the type of
anticoagulation was not associated with a reduced risk
of ischemic stroke. We do not have data on the presence
of concomitant stroke etiologies, some of which, such as
small vessel disease, might not respond well to anticoagu-
lants and could contribute to our results. However, other
mechanisms including off-label low-dose use of DOAC,
which has been described as a potential cause of ischemic
stroke despite DOAC therapy in prior studies,36 could
have played a role.
For those patients with recurrent cardioembolic stro-
kes, more research is needed to determine whether the
dynamics of anticoagulant activity37 or the different types
of anticoagulants and their pharmacokinetics (eg, a long,
sustained effect for VKA, a 2–4 hour high peak effect
every 24 hours for once-daily edoxaban and rivaroxaban,
or every 12 hours for twice-daily apixaban and dabigatran)
affect recurrence in these patients. Moreover, DOAC
switching might deserve further prospective investigation
in larger study populations given that network
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meta-analyses of available randomized controlled trials
have provided indirect evidence of differential safety and
efficacy profiles among available DOACs.38,39
Regardless of the underlying explanation, our find-
ings have clearly identified patients with AF who have
ischemic stroke despite oral anticoagulation as a group at
high risk of subsequent recurrence who require better pre-
vention strategies. Recent data suggest that combination
DOAC and antiplatelet therapy might be effective for
stroke prevention.40,41 Combination strategies, for exam-
ple adding antiplatelet therapy or left atrial appendage
occlusion to oral anticoagulation might merit further
investigation in controlled trials in patients with AF who
have “failed” oral anticoagulation by sustaining an ische-
mic stroke.
Our study has the following strengths: (1) we
included data from 7 international studies involving
patients from Europe and Asia (and 1 center in North
America), which makes our results broadly generalizable
worldwide; (2) we report on a large, stroke-unit based data
set of patients with a recent ischemic stroke and AF with
more than 5,000 patients and more than 6,000 patient-
years of follow-up; (3) all participating studies prospec-
tively recruited stroke patients (in the majority of cases
consecutively), minimizing selection bias; and (4) we
included patients at high risk for both ischemic stroke and
intracranial bleeding, with a median CHA2DS2-VASc
score of 5 and a HAS-BLED score of 3. Ninety-three per-
cent of our patients received any oral anticoagulation after
the index event, which suggests that the majority of
patients received best medical therapy to prevent further
events.
Our study has some limitations: (1) we report on an
observational study rather than a randomized trial, and
allocation to the type of oral anticoagulant is likely to be
affected by biases (including physician factors) that cannot
be fully adjusted for; (2) OACprior was determined by his-
tory only, and the time of last OAC intake was not avail-
able; (3) we did not record the reason for OACprior or the
etiology of index or follow-up strokes, and so can only
speculate on mechanisms of recurrent stroke; (4) we could
not determine whether patients pretreated with DOACs
received the appropriate dose based on their age, body
weight, and creatinine or estimated glomerular filtration
rate levels; (5) although the largest cohort of patients
reported with stroke while on treatment with anti-
coagulation, the sample size was insufficient to perform
in-depth analysis of different strategies to prevent further
events, and in particular was not powered to investi-
gate whether any specific type of anticoagulant is associ-
ated with a decreased risk for further events; (6) we did
not have data on concomitant atherosclerosis and small
vessel disease and other secondary prevention strategies
(statins, hypertensive agents) or other factors related to
confounding by indication (eg, hemorrhagic transforma-
tion, prior dementia, institutionalization, lack of social
support, etc, which could influence physicians’ decisions
to prescribe OAC); and (7) although one might expect
patients switched to a DOAC to have a lower rate of
ICH, this was not the case in this analysis, as the sub-
group analysis was not powered for this endpoint. How-
ever, in our prior analysis,4 patients taking DOACs after a
recent ischemic stroke had a significantly lower risk of
ICH compared to those taking VKA.
To summarize, we found that patients having a
stroke despite being on therapy with an oral anticoagulant
are at high risk of recurrent ischemic strokes. Further
research is needed to investigate mechanisms of recurrent
stroke and improve secondary prevention in these
patients.
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